Atilotrelvir

Atilotrelvir

Clinical data
Other names	GST-HG171
Identifiers
IUPAC name (1S,3S,4R)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-2-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]spiro[2-azabicyclo[2.2.1]heptane-5,1'-cyclopropane]-3-carboxamide
CAS Number	2850365-55-6
PubChem CID	167518234
DrugBank	DB19439
ChemSpider	129309388
UNII	JVV7PSN6VL
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C24H32F3N5O4
Molar mass	511.546 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)[C@@H](C(=O)N1[C@H]2C[C@@H]([C@H]1C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C4(C2)CC4)NC(=O)C(F)(F)F
InChI InChI=InChI=1S/C24H32F3N5O4/c1-22(2,3)17(31-21(36)24(25,26)27)20(35)32-14-9-15(23(10-14)5-6-23)16(32)19(34)30-13(11-28)8-12-4-7-29-18(12)33/h12-17H,4-10H2,1-3H3,(H,29,33)(H,30,34)(H,31,36)/t12-,13-,14-,15-,16-,17+/m0/s1 Key:GTRJFXDJASEGSW-KBCNZALWSA-N

Atilotrelvir (development code GST-HG171) is a drug for the treatment of COVID-19. It has broad-spectrum anti-SARS-CoV-2 activity against different variants (including WT, β, δ, and omicron).

In combination with ritonavir, it was approved for use in China in 2023.